https://orcid.org/0000-0002-9604-9655
Key Points
Unsupervised consensus clustering of cytokine profiles in 128 patients with TAM identified groups at higher risk for early death.
Measurement of levels of cytokine provides valuable information for patients with TAM that may help determine therapeutic interventions.
Transient abnormal myelopoiesis (TAM) occurs in 10% of neonates with Down syndrome (DS). Although most patients show spontaneous resolution of TAM, early death occurs in approximately 20% of cases. Therefore, new biomarkers are needed to predict early death and determine therapeutic interventions. This study aimed to determine the association between clinical characteristics and cytokine levels in patients with TAM. A total of 128 patients with DS with TAM enrolled in the TAM-10 study conducted by the Japanese Pediatric Leukemia/Lymphoma Study Group were included in this study. Five cytokine levels [interleukin (IL)-1b, IL-1 receptor agonist, IL-6, IL-8, and IL-13] were significantly higher in patients with early death than in those with non-early death. Cumulative incidence rates (CIR) of early death were significantly associated with high levels of the five cytokines. Based on unsupervised consensus clustering, patients were classified into three cytokine groups: hot-1 (n = 37), hot-2 (n = 42), and cold (n = 49). The CIR of early death was significantly different between the cytokine groups [hot-1/2 (n = 79); cold (n = 49); CIR (95% confidence interval [CI]) = 16.5% (7.9%-24.2%); 2.0% (0.0%-5.9%), P = 0.013]. Furthermore, cytokine groups (hot-1/2 vs. cold) were independent poor prognostic factors in the multivariable analysis for early death [hazard ratio (95% CI) = 19.25 (2.056-180.3), P = 0.010]. These results provide valuable information that cytokine level measurement was useful in predicting early death in patients with TAM and might help to determine the need for therapeutic interventions.
